Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: The beneficial effects of adjunctive pramlintide and liraglutide

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1127-1134

  Sherr, Jennifer L ^a   Patel, Neha S ^a   Michaud, Camille I ^a   Palau Collazo, Miladys M ^a   Van Name, Michelle A ^a   Tamborlane, William V ^a   Cengiz, Eda ^a   Carria, Lori R ^a   Tichy, Eileen M ^a   Weinzimer, Stuart A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; LIRAGLUTIDE; PRAMLINTIDE; AMYLIN; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INSULIN;

ADOLESCENT; ADULT; BLOATING; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONFERENCE PAPER; CONSTIPATION; DECREASED APPETITE; DIARRHEA; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN PUMP; LOSS OF APPETITE; MORNING DOSAGE; NAUSEA; OUTPATIENT CARE; POSTPRANDIAL STATE; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT REDUCTION; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DRUG EFFECTS; FEMALE; HYPERGLYCEMIA; MALE; MEAL; METABOLISM; PHYSIOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; ISLET AMYLOID POLYPEPTIDE; LIRAGLUTIDE; MALE; MEALS; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84975822111     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0089     Document Type: Conference Paper

References (26)

1. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. Anartificial endocrine pancreas. Diabetes 1974;23:389-396
2. Albisser AM, Leibel BS, Ewart TG, et al. Clinical controlofdiabetesby the artificial pancreas. Diabetes 1974;23:397-404
3. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automatinginsulin delivery for the treatment of type 1 diabetes. Diabetes 2006;55:3344-3350
4. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care 2008;31:934-939
5. Hovorka R, Allen JM, Elleri D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 2010;375:743-751
6. Hovorka R, Kumareswaran K, Harris J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ 2011;342:d1855
7. Kovatchev B, Cobelli C, Renard E, et al. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol 2010;4:1374-1381
8. Nimri R, Atlas E, Ajzensztejn M, Miller S, Oron T, Phillip M. Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. Diabetes Technol Ther 2012;14:728-735
9. Nimri R, Danne T, Kordonouri O, et al. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Pediatr Diabetes 2013; 14:159-167
10. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bihormonal bionic endocrine pancreas. Diabetes Care 2012;35:2148-2155
11. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010;33:1282-1287
12. Haidar A, Legault L, Dallaire M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 2013;185:297-305
13. Van Bon AC, Jonker LD, Koebrugge R, Koops R, Hoekstra JB, DeVries JH. Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions. J Diabetes Sci Technol 2012;6:1114-1122
14. Pinsker JE, Lee JB, Dassau E, et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care 2016;39:1135-1142
15. Anderson SM, Raghinaru D, Pinsker JE, et al. Multinational home use of closed-loop control is safe and effective. Diabetes Care 2016; 39:1143-1150
16. Renard E, Farret A, Kropff J, et al.; AP@home Consortium. Day-and-night closed-loop glucose control in patients with type I diabetes under free-living conditions: results of a single-arm 1-month experience compared with a previously reported feasibility study of evening and night at home. Diabetes Care 2016;39:1151-1160
17. Tauschmann M, Allen JM, Wilinska ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 2016;39:1168-1174
18. Del Favero S, Boscari F, Messori M, et al. Randomized summer camp crossover trial in 5-to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care 2016;39:1180-1185
19. Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care 2012;35:1994-1999
20. Nauck M.A. Is glucagon-like peptide 1 an incre-tin hormone? Diabetologia 1999;42:373-379
21. Steil GM, Palerm CC, Kurtz N, et al. The effectof insulin feedback on closed loop glucose control. J Clin Endocrinol Metab 2011;96:1402-1408
22. Palerm CC. Physiologic insulin delivery with insulin feedback: a control systems perspective. Comput Methods Programs Biomed 2011;102:130-137
23. Hare KJ, Knop FK, Asmar M, et al. Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2diabetes mellitus. J Clin Endocrinol Metab 2009;94:4679-4687
24. Kramer CK, Zinman B, Choi H, Connelly PW, Retnakaran R. The impact of chronic liraglutide therapy on glucagon secretion in type 2 diabetes: insight from the LIBRA trial. J Clin Endocrinol Metab 2015;100:3702-3709
25. Chillarón JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. Metabolism 2014;63:181-187
26. Libman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA 2015;314:2241-2250